RxDoctor Payments Data

Michelle Russell

Family · San Francisco, CANPI 1336822519

Payments from drug & device makers

$2,259in general payments, 2019–2025

Across 75 payments — averaging $30.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$176
  • Seagen Inc.$136
  • AstraZeneca$128
  • AbbVie$123
  • AVEO Pharmaceuticals, Inc.$121
  • Geron Corporation$118
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$2,07292%
  • Education$1878%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,259 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
Darzalex FasproDaratumumab-Hyaluronidase-Fihj32$196,283
Neulasta OnproPegfilgrastim29$180,381
OpdivoNivolumab18$157,177
KeytrudaPembrolizumab12$135,617
NubeqaDarolutamide13$83,910
XgevaDenosumab19$58,288
AranespDarbepoetin Alfa In Polysorbat27$51,320
ZirabevBevacizumab-Bvzr15$50,370
AvastinBevacizumab11$33,347
OrgovyxRelugolix11$28,227
AlymsysBevacizumab-Maly11$26,749
NplateRomiplostim13$16,766
EliquisApixaban24$15,162
Leucovorin Calcium63$9,742
Bortezomib11$6,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckKeytruda$96$135,61712 claims
BayerNubeqa$61$83,91013 claims
PfizerZirabev, Eliquis$96$65,53239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →